These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1220910)

  • 1. New concepts in the immunotherapy of neoplasms.
    Rosato FE; Miller EE; Rosato EF
    Compr Ther; 1975 Aug; 1(4):15-23. PubMed ID: 1220910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunotherapy of prostate cancer].
    Schulze H; Sommerfeld HJ
    Urologe A; 1993 Sep; 32(5):382-9. PubMed ID: 8212423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology?
    Fry TJ; Lankester AC
    Pediatr Clin North Am; 2008 Feb; 55(1):147-67, xi. PubMed ID: 18242319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A malignus melanoma immunterápiájának lehetoségei].
    Ladányi A
    Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of renal cell carcinoma.
    deKernion JB
    Prog Clin Biol Res; 1984; 153():409-21. PubMed ID: 6206509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant treatment of minimal residual tumors. A comparison of chemotherapy and immunotherapy.
    Mathé G; Reizenstein P; Eriguchi M
    Bull Soc Sci Med Grand Duche Luxemb; 1989; 126(1):75-92. PubMed ID: 2663216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant immunotherapy for solid tumors: from promise to clinical application.
    Mocellin S; Rossi CR; Lise M; Marincola FM
    Cancer Immunol Immunother; 2002 Dec; 51(11-12):583-95. PubMed ID: 12439603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of immunotherapy for the treatment of malignancies refractory to conventional therapies.
    Kim S; Haas GP; Hillman GG
    Cytokines Mol Ther; 1996 Mar; 2(1):13-9. PubMed ID: 9384685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
    Zöller M; Matzku S
    Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunotherapy for cancer--modern immunologic strategies in oncology].
    Halama N; Zoernig I; Jäger D
    Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Passive, adoptive, and active immunotherapy: a review of clinical trials in cancer.
    Mathé G
    Cancer Detect Prev Suppl; 1987; 1():279-90. PubMed ID: 3319146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bio-immunotherapy for cancer in experimental studies and clinical application: current status and future challenges.
    Shen RN; Lu L; Kaiser HE; Broxmeyer HE
    In Vivo; 1994; 8(5):643-52. PubMed ID: 7727711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic specific active immunotherapy for solid tumors. An overview about cancer vaccinetherapy.
    Tagliaferri F; Sirovich I; Stipa F; Valente MG; Pupelis G; Tremiterra S
    Recenti Prog Med; 1994 Dec; 85(12):591-6. PubMed ID: 7899685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
    Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
    Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of optimized cryptic peptides for immunotherapy.
    Menez-Jamet J; Kosmatopoulos K
    IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vaccine therapy of malignant tumors].
    Csatáry L; Gergely P
    Orv Hetil; 1990 Nov; 131(47):2585-8. PubMed ID: 2247306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy of solid tumors. Clinical studies].
    Tagliaferri F; Valente MG; Stipa F; Cesareo S
    Recenti Prog Med; 1996; 87(7-8):362-5. PubMed ID: 8975339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.